$-0.32 EPS Expected for Iovance Biotherapeutics, Inc. (IOVA)

July 13, 2018 - By Hugh Holland

Analysts expect Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) to report $-0.32 EPS on August, 7.They anticipate $0.05 EPS change or 13.51 % from last quarter’s $-0.37 EPS. After having $-0.31 EPS previously, Iovance Biotherapeutics, Inc.’s analysts see 3.23 % EPS growth. The stock increased 4.14% or $0.55 during the last trading session, reaching $13.85. About 622,233 shares traded. Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) has risen 159.35% since July 13, 2017 and is uptrending. It has outperformed by 146.78% the S&P500.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company has market cap of $1.24 billion. The company's lead product candidate is LN-144, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes , which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It currently has negative earnings. It is also developing LN-145 to treat cervical and head and neck cancers.

More news for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) were recently published by: Seekingalpha.com, which released: “Boston Scientific Is A Good Earnings Story – Cramer’s Lightning Round (6/13/18)” on June 14, 2018. Streetinsider.com‘s article titled: “Iovanace Biotherapeutics (IOVA) PT Maintained at $30 at Chardan Capital Markets; ‘Market Misunderstandings’ Offer …” and published on July 06, 2018 is yet another important article.

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.